

## **INSTRUCTIONS FOR ABSTRACTS**

In order to facilitate the formatting and printing of the final program, the Organizing Committee strongly encourage you to follow the instructions provided below:

**Title : Time 13 pts Bold Capitals,**

**Authors : Times 12pts**

First and last names in full, with affiliations indicated with superscript numbers,  
**Affiliations : Times 12 pts** Laboratory/Department, Institution, City, State,  
Country

**Body of the abstract : Times 12pts Word limit : 400**

**See below an example of abstract for recommended format.**

**DEADLINE FOR ABSTRACT SUBMISSION IS AUGUST 1st, 2019**

## CCN1 IN INTESTINAL MUCOSAL HEALING

Jacob S. Choi, Ki-Hyun Kim, Joon-Il Jun, and Lester F. Lau

Department of Biochemistry and Molecular Genetics  
University of Illinois at Chicago College of Medicine  
Chicago, IL 60607

Crohn's disease (CD) and ulcerative colitis (UC), two major subtypes of inflammatory bowel disease (IBD), are chronic inflammatory disorders of poorly defined etiology. Traditional therapies have focused on amelioration of inflammation, although recent studies have indicated that mucosal healing is an important prognostic endpoint. The integrin-binding matricellular protein CCN1 (CYR61) is upregulated in human patients with CD and UC, and is emerging as a key injury response molecule that coordinates multiple aspects of wound healing and tissue repair in colitis. Knockin mice expressing integrin-binding defective CCN1 suffer exacerbated morbidity and mortality in experimental colitis, showing impaired epithelial regeneration, neutrophil persistence, and elevated fibrosis. Furthermore, treatment of wild-type or *Ccn1* mutant mice with purified CCN1 protein significantly accelerates mucosal healing from colitis, suggesting a therapeutic potential of CCN1 for IBD. Here we will discuss the role of CCN1 in mucosal healing and intestinal injury repair following experimental colitis.